Lansoprazole (AG 1749) 是质子泵抑制剂,能抑制胃酸生成。Lansoprazole (AG 1749) 是中性鞘磷脂酶(N-SMase)的抑制剂(外泌体抑制剂)。
生物活性 | Lansoprazole (AG 1749) is an orally activeproton pump inhibitorwhich prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrantneutral sphingomyelinase (N-SMase)inhibitor (exosome inhibitor)[1][2]. |
体外研究 (In Vitro) | Lansoprazole from 0.3 to 3 μM inhibits gastric acid formation in a concentration-dependent manner (IC50of 0.76 μM)[4]. Lansoprazole (30-300 μM) both induced concentration-dependent, reversible and reproducible relaxations of arteries[5].
|
体内研究 (In Vivo) | Lansoprazole (20-40 mg/kg) treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations[3]. Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced increase in AChE activity[3]. Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced rise in brain MPO level[3]. Further HFD mice treated with lansoprazole (20 mg/kg and 40 mg/kg, p.o.) shows a marked decrease in the body weight in comparison to the control animals[3].
Animal Model: | Swiss albino mice (20–25 g) of either sex[3]. | Dosage: | 20 mg/kg, 40 mg/kg. | Administration: | PO, started after second dose of STZ and then subjected to MWM test. Continued (30 min before) during the acquisition trial conducted from day 1 to day 4. | Result: | Significantly attenuated the day 4 rise in ELT and decreased in day 5 TSTQ in the STZ as well as HFD treated mice in a dose dependent manner. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(270.74 mM;Need ultrasonic) H2O : 0.1 mg/mL(0.27 mM;Need ultrasonic) 配制储备液 1 mM | 2.7074 mL | 13.5369 mL | 27.0739 mL | 5 mM | 0.5415 mL | 2.7074 mL | 5.4148 mL | 10 mM | 0.2707 mL | 1.3537 mL | 2.7074 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.77 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.77 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|